SINGAPORE CANCER SOCIETY

(UEN: S65SS0033F)

Statement by the Council and Financial Statements

Year Ended 31 December 2015

RSM Chio Lim LLP

8 Wilkie Road, #03-08
Wilkie Edge, Singapore 228095

T +65 6533 7600
F +65 6594 7811

Audit@RSMSingapore.sg
www.RSMSingapore.sg

UEN: T09LL0008J

RSM Chio Lim LLP is a member of the RSM network and trades as RSM. RSM is the trading name used by the members of the RSM network. Each member of the RSM network is an independent accounting and consulting firm which practices in its own right. The RSM network is not itself a separate legal entity in any jurisdiction.

Business Advisors to Growing Businesses

Statement by the Council and Financial Statements

Contents **Page**

Statement by the Council	1
Independent Auditor's Report	2
Statement of Financial Activities	4
Statement of Financial Position	6
Statement of Changes in Funds	7
Statement of Cash Flows	8
Notes to the Financial Statements	9
Statement of Financial Activities – Supplementary Schedules	28

Statement by the Council

In the opinion of the Council, the accompanying financial statements are drawn up so as to present fairly, in all material respects, the state of affairs of the Society as at 31 December 2015 and the results, changes in funds and cash flows of the Society for the reporting year ended on that date and at the date of this statement there are reasonable grounds to believe that the Society will be able to pay its debts as and when they fall due.

On Behalf of the Council



.....
Choo Eng Chuan
Chairman



.....
Ang Ai-Ming
Honorary Secretary

.....
Lim Pek Suat
Honorary Treasurer

Singapore

30 March 2016

RSM Chio Lim LLP

8 Wilkie Road, #03-08
Wilkie Edge, Singapore 228095

T +65 6533 7600
F +65 6594 7811

Audit@RSMSingapore.sg
www.RSMSingapore.sg

Independent Auditor's Report to the members of the Singapore Cancer Society (UEN: S65SS0033F)

Report on the financial statements

We have audited the accompanying financial statements of Singapore Cancer Society (the "Society") which comprise the statement of financial position as at 31 December 2015, and the statement of financial activities, statement of changes in funds and statement of cash flows for the reporting year then ended, and a summary of significant accounting policies and other explanatory information.

Management's responsibility for the financial statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with the Singapore Financial Reporting Standards and the Societies Act, Chapter 311 (the "Societies Act"), and the Charities Act, Chapter 37 (the "Charities Act"), and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with Singapore Standards on Auditing. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

UEN 1031L0009J

RSM Chio Lim LLP is a member of the RSM network and trades as RSM. RSM is the trading name used by the members of the RSM network. Each member of the RSM network is an independent accounting and consulting firm which practices in its own right. The RSM network is not itself a separate legal entity in any jurisdiction.

Business Advisors to Growing Businesses

Independent Auditor's Report to the members of the Singapore Cancer Society (UEN: S65SS0033F)

Opinion

In our opinion, the financial statements are properly drawn up in accordance with the Singapore Financial Reporting Standards so as to present fairly, in all material respects, the state of affairs of the Society as at 31 December 2015 and the results, changes in funds and cash flows of the Society for the reporting year ended on that date.

Report on other legal and regulatory requirements

In our opinion:

(a) The accounting and other records required by the regulations enacted under the Societies Act to be kept by the Society have been properly kept in accordance with those regulations; and

(b) The fund-raising appeals held during the reporting year have been carried out in accordance with regulation 6 of the Societies Regulations issued under the Societies Act and proper accounts and other records have been kept of the fund-raising appeal.

During the course of our audit, nothing has come to our attention that causes us to believe that during the reporting year:

(a) The use of the donation monies was not in accordance with the objectives of the Society as required under regulation 11 of the Charities (Institutions of a Public Character) Regulations; and

(b) The Society has not complied with the requirements of regulation 15 (Fund-raising expenses) of the Charities (Institutions of a Public Character) Regulations.

RSM Chio Lim LLP
Public Accountants and
Chartered Accountants
Singapore

30 March 2016

Partner-in-charge of audit: Woo E-Sah
Effective from year ended 31 December 2015

SINGAPORE CANCER SOCIETY (UEN: S65SS0033F)

Statement of Financial Activities
For the Reporting Year Ended 31 December 2015

2015

	Note	Unrestricted funds				Restricted funds				
		General Fund	Cancer Treatment Fund	SCS-CST Matching Fund	Sub-Total	Run For Hope Fund	RGS-Joan Chan Shu Fang Fund	Movember Fund	Sub-Total	Total
		$	$		$	$	$	$	$	$
INCOME										
Voluntary income		17,093,065	–	–	17,093,065	–	–	–	–	17,093,065
Voluntary Income: Hospice		1,000,000	–	–	1,000,000	–	–	–	–	1,000,000
Charitable income		1,505	–	–	1,505	–	–	–	–	1,505
Funds generating activities	4	4,292,947	–	–	4,292,947	–	–	855,150	855,150	5,148,097
Investment income		587,832	–	–	587,832	–	–	–	–	587,832
Sundry income		1,113,565	–	–	1,113,565	7,739	–	–	7,739	1,121,304
Total income		24,088,914	–	–	24,088,914	7,739	–	855,150	862,889	24,951,803
EXPENSES				–			–			
Costs of generating voluntary income: Fund raising		728,674	–	–	728,674	–	–	–	–	728,674
Costs of charitable activities: Cancer screening, public education and research		4,042,088	–	–	4,042,088	–	–	–	–	4,042,088
Costs of charitable activities: Welfare Services		5,266,316	939,572	–	6,205,888	–	–	59,764	59,764	6,265,652
Costs of charitable activities: Hospice homecare and support group expenses		2,043,850	–	–	2,043,850	–	–	–	–	2,043,850
Costs of charitable activities: Cancer Rehab		769,416	–	–	769,416	–	–	–	–	769,416
Costs of fund generating activities	4	1,839,496	–	–	1,839,496	–	–	141,258	141,258	1,980,754
Administrative costs		290,201	–	–	290,201	–	–	–	–	290,201
Total expenses		14,980,041	939,572	–	15,919,613	–	–	201,022	201,022	16,120,635
Surplus/(deficit) for the reporting year		9,108,873	(939,572)	–	8,169,301	7,739	–	654,128	661,867	8,831,168
Balance at 1 January 2015		50,186,659	32,720	5,000,000	55,219,379	80,355	23,311	997,938	1,101,604	56,320,983
Transfer to/(from) funds		(10,210,056)	10,000,000	–	–	–	–	210,056	210,056	–
Balance at 31 December 2015		49,085,476	9,093,148	5,000,000	63,178,624	88,094	23,311	1,862,122	1,973,527	65,152,151

A further analysis of the above items is presented in the supplementary schedules.

The accompanying notes form an integral part of these financial statements.

Statement of Financial Activities
For the Reporting Year Ended 31 December 2015

2014		Unrestricted funds					Restricted funds					
	Note	General Fund	Cancer Treatment Fund	Cervical Cancer Prevention Fund	SCS-CST Matching Fund	Sub-Total	Run For Hope Fund	RGS-Joan Chan Shu Fang Fund	Koh Soh Eng Fund	Movember Fund	Sub-Total	Total
		$	$	$		$	$	$	$	$	$	$
INCOME												
Voluntary income		11,818,470	32,720	4,000	–	11,855,190	–	5,623	(32,720)	–	(27,097)	**11,828,093**
Voluntary Income: Hospice		5,000,000	–	–	–	5,000,000	–	–	–	–	–	**5,000,000**
Charitable income		958	–	–	–	958	–	–	–	–	–	**958**
Funds generating activities	4	2,959,941	–	–	–	2,959,941	–	–	–	783,280	783,280	**3,743,221**
Investment income		260,892	–	–	–	260,892	–	–	–	–	–	**260,892**
Sundry income		560,318	–	–	–	560,318	37,921	–	–	–	37,921	**598,239**
Total income		20,600,579	32,720	4,000	–	20,637,299	37,921	5,623	(32,720)	783,280	794,104	**21,431,403**
EXPENSES												
Costs of generating voluntary income: Fund raising		1,589,070	–	–	–	1,589,070	–	–	–	–	–	**1,589,070**
Costs of charitable activities: Cancer screening, public education and research		3,215,249	–	84,300	–	3,299,549	–	–	–	–	–	**3,299,549**
Costs of charitable activities: Welfare Services		4,296,087	–	–	–	4,296,087	–	5,417	–	–	5,417	**4,301,504**
Costs of charitable activities: Hospice homecare and support group expenses		1,692,267	–	–	–	1,692,267	–	–	–	–	–	**1,692,267**
Costs of fund generating activities	4	1,595,677	–	–	–	1,595,677	–	–	–	320,628	320,628	**1,916,305**
Administrative costs		1,089,202	–	–	–	1,089,202	30	–	–	–	30	**1,089,232**
Total expenses		13,477,552	–	84,300	–	13,561,852	30	5,417	–	320,628	326,075	**13,887,927**
Surplus/(deficit) for the reporting year		7,123,027	32,720	(80,300)	–	7,075,447	37,891	206	(32,720)	462,652	468,029	**7,543,476**
Balance at 1 January 2014		43,047,970	–	80,300	5,015,662	48,143,932	42,464	23,105	32,720	535,286	633,575	**48,777,507**
Transfer to/(from) general funds		15,662	–	–	(15,662)	–	–	–	–	–	–	–
Balance at 31 December 2014		50,186,659	32,720	–	5,000,000	55,219,379	80,355	23,311	–	997,938	1,101,604	**56,320,983**

A further analysis of the above items is presented in the supplementary schedules.

The accompanying notes form an integral part of these financial statements.

Statement of Financial Position
As at 31 December 2015

	Note	2015 $	2014 $
ASSETS			
Non-current assets			
Property, plant and equipment	9	3,482,742	2,306,337
Other financial assets, non - current	10	22,379,925	8,000,000
Total non-current assets		25,862,667	10,306,337
Current assets			
Inventories	11	9,768	285
Other receivables	12	1,437,053	1,482,896
Other financial assets, current	10	4,000,000	–
Other assets	13	606,022	286,042
Cash and cash equivalents	14	40,231,087	50,321,662
Total current assets		46,283,930	52,090,885
Current liabilities			
Trade payables	15	2,872,952	2,281,008
Other liabilities	16	4,121,494	3,795,231
Total current liabilities		6,994,446	6,076,239
Net current assets		39,289,484	46,014,646
Net assets		65,152,151	56,320,983
THE FUNDS OF THE SOCIETY			
Unrestricted funds			
General Fund		49,085,476	50,186,659
Cancer Treatment Fund		9,093,148	32,720
SCS-CST Matching Fund		5,000,000	5,000,000
Total unrestricted funds		63,178,624	55,219,379
Restricted funds			
Run for Hope Fund		88,094	80,355
Rgs - Joan Chan Shu Fang Fund		23,311	23,311
Movember Fund		1,862,122	997,938
Total restricted funds		1,973,527	1,101,604
Total funds	17	65,152,151	56,320,983

The accompanying notes form an integral part of these financial statements.

Statement of Changes in Funds
For the Reporting Year Ended 31 December 2015

	Note	2015 $	2014 $
Balance at beginning of year		56,320,983	48,777,507
Net surplus for the reporting year		8,831,168	7,543,476
Balance at end of year		65,152,151	56,320,983

The accompanying notes form an integral part of these financial statements.

Statement of Cash Flows
For the Reporting Year Ended 31 December 2015

	2015 $	2014 $
Cash flows from operating activities		
Net surplus for the reporting year	8,831,168	7,543,476
Depreciation of property, plant and equipment	305,556	174,962
Loss on disposal of property, plant and equipment	433	5,367
Interest income	(587,832)	(260,892)
Property, plant and equipment received in kind	-	(100,000)
Operating cash flow before changes in working capital	8,549,325	7,362,913
Inventories	(9,483)	705
Other receivables	211,266	(1,103,419)
Other assets	(319,980)	(204,932)
Cash restricted under specific funds	(326,263)	1,120,746
Cash restricted in use over 3 months	(7,983,725)	9,017,965
Trade payables	591,944	615,240
Other liabilities	326,263	(1,120,746)
Net cash flows from operating activities	1,039,347	15,688,472
Cash flows from investing activities		
Other financial assets, non-current	(18,379,925)	–
Purchase of property, plant and equipment	(1,482,394)	(360,703)
Interest received	422,409	265,027
Net cash flows used in investing activities	(19,439,910)	(95,676)
Net (decrease)/increase in cash and cash equivalents	(18,400,563)	15,592,796
Cash and cash equivalents, cash flow statement, beginning Balance	44,494,540	28,901,744
Cash and cash equivalents, cash flow statement, ending Balance (Note 14A)	26,093,977	44,494,540

The accompanying notes form an integral part of these financial statements.

Notes to the Financial Statements
For the Reporting Year Ended 31 December 2015

1. General

The principal objectivities of the Singapore Cancer Society (the "Society") are those of a community-based voluntary health organisation dedicated to minimising the impact of cancer through public education, screening, patient service, financial assistance, research and advocacy.

The Society is established in Singapore under the Societies Act, Chapter 311. It is also subject to the provisions of the Charities Act, Chapter 37. It is an Institution of a Public Character.

The constitution of the Society restricts the use of fund monies to the furtherance of the objects of the Society. It prohibits the payment of dividends to members. The Society has no share capital.

The functional currency of the Society is Singapore dollars and the financial statements are presented in Singapore dollars.

The Society is registered and situated in Singapore. The registered office address is: 15 Enggor Street, #04-01 to 04 Realty Centre, Singapore 079716.

The financial statements were approved and authorised for issue by the Council of the Society on the date indicated in the statement by the Council.

2. Summary of significant accounting policies

Accounting convention

The financial statements have been prepared in accordance with the Singapore Financial Reporting Standards ("FRS") and the related Interpretations to FRS ("INT FRS") as issued by the Singapore Accounting Standards Council. The financial statements are prepared on a going concern basis under the historical cost convention except where an FRS requires an alternative treatment (such as fair values) as disclosed where appropriate in these financial statements. The accounting policies in FRSs need not be applied when the effect of applying them is immaterial. The disclosures required by FRSs need not be made if the information is immaterial. The Society is also subject to the provisions of the Charities Act, Chapter 37.

Basis of preparation of the financial statements

The preparation of financial statements in conformity with generally accepted accounting principles requires the management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The estimates and assumptions are reviewed on an ongoing basis. Apart from those involving estimations, management has made judgements in the process of applying the Society's accounting policies. The areas requiring management's most difficult, subjective or complex judgements, or areas where assumptions and estimates are significant to the financial statements, are disclosed at the end of this footnote, where applicable.

2. Summary of significant accounting policies (cont'd)

Revenue recognition

The revenue amount is the fair value of the consideration received or receivable from the gross inflow of economic benefits during the year arising from the course of the ordinary activities of the Society and it is shown net of related tax.

(i) Donations and corporate cash sponsorships

Revenue from donations and corporate cash sponsorships are accounted for when received, except for committed donations and corporate cash sponsorships that are recorded when the commitments are signed.

(ii) Fund raising

Revenue from special event is recognised when the event takes place.

(iii) Other revenue

Interest revenue is recognised on a time-proportion basis using the effective interest rate that takes into account the effective yield on the asset.

Gifts in kind

A gift in kind is recognised based on an estimate of the fair value at the date of the receipt of the gift of the non-monetary asset or the grant of a right to the monetary asset. The gift is recognised if the amount of the gift can be measured reliably and there is no uncertainty that it will be received.

Grants

A grant is recognised at fair value when there is reasonable assurance that the conditions attaching to it will be complied with and that the grant will be received. Grants in recognition of specific expenses are recognised as income over the periods necessary to match them with the related costs that they are intended to compensate, on a systematic basis. Grants related to depreciable assets are allocated to income over the period in which such assets are used in the project subsidised by the grant. A government grant related to assets, including non-monetary grants at fair value, is presented in the statement of financial position by setting up the grant as deferred income.

Income tax

As a charity, the Society is exempt from tax on income and gains falling within section 13U(1) of the Income Tax Act to the extent that these are applied to its charitable objects.

2. Summary of significant accounting policies (cont'd)

Employee benefits

Contributions to a defined contribution retirement benefit plan are recorded as an expense as they fall due. The entity's legal or constructive obligation is limited to the amount that it agrees to contribute to an independently administered fund (such as the Central Provident Fund in Singapore, a government managed defined contribution retirement benefit plan). For employee leave entitlement the expected cost of short-term employee benefits in the form of compensated absences is recognised in the case of accumulating compensated absences, when the employees render service that increases their entitlement to future compensated absences; and in the case of non-accumulating compensated absences, when the absences occur. A liability for bonuses is recognised where the entity is contractually obliged or where there is constructive obligation based on past practice.

Property, plant and equipment

Depreciation is provided on a straight-line basis to allocate the gross carrying amounts of the assets less their residual values over their estimated useful lives of each part of an item of these assets. The annual rates of depreciation are as follows:

Freehold office premises	2%
Computers	33 $^{1}/_{3}$%
Furniture and fittings	20%
Motor vehicles	10%

An asset is depreciated when it is available for use until it is derecognised even if during that period the item is idle. Fully depreciated assets still in use are retained in the financial statements.

Property, plant and equipment are carried at cost on initial recognition and after initial recognition at cost less any accumulated depreciation and any accumulated impairment losses. The gain or loss arising from the derecognition of an item of property, plant and equipment is measured as the difference between the net disposal proceeds, if any, and the carrying amount of the item and is recognised in profit or loss. The residual value and the useful life of an asset is reviewed at least at each end of the reporting year and, if expectations differ significantly from previous estimates, the changes are accounted for as a change in an accounting estimate, and the depreciation charge for the current and future periods are adjusted.

Cost also includes acquisition cost, borrowing cost capitalised and any cost directly attributable to bringing the asset or component to the location and condition necessary for it to be capable of operating in the manner intended by management. Subsequent costs are recognised as an asset only when it is probable that future economic benefits associated with the item will flow to the entity and the cost of the item can be measured reliably. All other repairs and maintenance are charged to profit or loss when they are incurred.

2. Summary of significant accounting policies (cont'd)

Leases

Leases where the lessor effectively retains substantially all the risks and benefits of ownership of the leased assets are classified as operating leases. For operating leases, lease payments are recognised as an expense in profit or loss on a straight-line basis over the term of the relevant lease unless another systematic basis is representative of the time pattern of the user's benefit, even if the payments are not on that basis. Lease incentives received are recognised in profit or loss as an integral part of the total lease expense.

Inventories

Inventories are measured at the lower of cost (first in first out method) and net realisable value. A write down on cost is made for where the cost is not recoverable or where applicable if the selling prices have declined. Cost includes all costs of purchase, costs of conversion and other costs incurred in bringing the inventories to their present location and condition.

Impairment of non-financial assets

Irrespective of whether there is any indication of impairment, an annual impairment test is performed at the same time every year on an intangible asset with an indefinite useful life or an intangible asset not yet available for use. The carrying amount of other non-financial assets is reviewed at each end of the reporting year for indications of impairment and where an asset is impaired, it is written down through profit or loss to its estimated recoverable amount. The impairment loss is the excess of the carrying amount over the recoverable amount and is recognised in profit or loss. The recoverable amount of an asset or a cash-generating unit is the higher of its fair value less costs of disposal and its value in use. When the fair value less costs of disposal method is used, any available recent market transactions are taken into consideration. When the value in use method is adopted, in assessing the value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows (cash-generating units). At each end of the reporting year non-financial assets other than goodwill with impairment loss recognised in prior periods are assessed for possible reversal of the impairment. An impairment loss is reversed only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been measured, net of depreciation or amortisation, if no impairment loss had been recognised.

Financial assets

Initial recognition, measurement and derecognition:

A financial asset is recognised on the statement of financial position when, and only when, the entity becomes a party to the contractual provisions of the instrument. The initial recognition of financial assets is at fair value normally represented by the transaction price. The transaction price for financial asset not classified at fair value through profit or loss includes the transaction costs that are directly attributable to the acquisition or issue of the financial asset. Transaction costs incurred on the acquisition or issue of financial assets classified at fair value through profit or loss are expensed immediately. The transactions are recorded at the trade date.

2. Summary of significant accounting policies (cont'd)

Financial assets (cont'd)

Irrespective of the legal form of the transactions performed, financial assets are derecognised when they pass the "substance over form" based on the derecognition test prescribed by FRS 39 relating to the transfer of risks and rewards of ownership and the transfer of control. Financial assets and financial liabilities are offset and the net amount is reported in the statement of financial position if there is currently a legally enforceable right to offset the recognised amounts and there is an intention to settle on a net basis, to realise the assets and settle the liabilities simultaneously.

Subsequent measurement:

Subsequent measurement based on the classification of the financial assets in one of the following four categories under FRS 39 is as follows:

1. Financial assets at fair value through profit or loss: As at end of reporting year date there were no financial assets classified in this category.

2. Loans and receivables: Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. Assets that are for sale immediately or in the near term are not classified in this category. These assets are carried at amortised costs using the effective interest method (except that short-duration receivables with no stated interest rate are normally measured at original invoice amount unless the effect of imputing interest would be significant) minus any reduction (directly or through the use of an allowance account) for impairment or uncollectibility. Impairment charges are provided only when there is objective evidence that an impairment loss has been incurred as a result of one or more events that occurred after the initial recognition of the asset (a 'loss event') and that loss event (or events) has an impact on the estimated future cash flows of the financial asset or group of financial assets that can be reliably estimated. The methodology ensures that an impairment loss is not recognised on the initial recognition of an asset. Losses expected as a result of future events, no matter how likely, are not recognised. For impairment, the carrying amount of the asset is reduced through use of an allowance account. The amount of the loss is recognised in profit or loss. An impairment loss is reversed if the reversal can be related objectively to an event occurring after the impairment loss was recognised. Typically the trade and other receivables are classified in this category.

3. Held-to-maturity financial assets: These are non-derivative financial assets with fixed or determinable payments and fixed maturity that the entity has positive intention and ability to hold to maturity. Financial assets that upon initial recognition are designated as at fair value through profit or available-for-sale and those that meet the definition of loans and receivables are not classified in this category. These assets are carried at amortised costs using the effective interest method minus any reduction (directly or through the use of an allowance account) for impairment or uncollectibility Impairment charges are provided only when there is objective evidence that an impairment loss has been incurred. For impairment, the carrying amount of the asset is reduced through use of an allowance account. The gains and losses are recognised in profit or loss when the investments are derecognised or impaired, as well as through the amortisation process. Impairment losses recognised in profit or loss are subsequently reversed if an increase in the fair value of the instrument can be objectively related to an event occurring after the recognition of the impairment loss. Non-current investments in bonds and debt securities are usually classified in this category.

4. Available-for-sale financial assets: As at end of the reporting year date, there were no financial assets classified in this category.

2. **Summary of significant accounting policies (cont'd)**

Cash and cash equivalents

Cash and cash equivalents include bank and cash balances and any highly liquid debt instruments purchased with an original maturity of three months or less. For the statement of cash flows the item includes cash and cash equivalents less cash subject to restriction and bank overdrafts payable on demand that form an integral part of cash management.

Financial liabilities

Initial recognition, measurement and derecognition:

A financial liability is recognised on the statement of financial position when, and only when, the entity becomes a party to the contractual provisions of the instrument and it is derecognised when the obligation specified in the contract is discharged or cancelled or expires. The initial recognition of financial liability is at fair value normally represented by the transaction price. The transaction price for financial liability not classified at fair value through profit or loss includes the transaction costs that are directly attributable to the acquisition or issue of the financial liability. Transaction costs incurred on the acquisition or issue of financial liability classified at fair value through profit or loss are expensed immediately. The transactions are recorded at the trade date. Financial liabilities including bank and other borrowings are classified as current liabilities unless there is an unconditional right to defer settlement of the liability for at least 12 months after the end of the reporting year.

Subsequent measurement:

Subsequent measurement based on the classification of the financial liabilities in one of the following two categories under FRS 39 is as follows:

1. Liabilities at fair value through profit or loss: Liabilities are classified in this category when they are incurred principally for the purpose of selling or repurchasing in the near term (trading liabilities) or are derivatives (except for a derivative that is a designated and effective hedging instrument) or have been classified in this category because the conditions are met to use the "fair value option" and it is used. Financial guarantee contracts if significant are initially recognised at fair value and are subsequently measured at the greater of (a) the amount measured in accordance with FRS 37 and (b) the amount initially recognised less, where appropriate, cumulative amortisation recognised in accordance with FRS 18. All changes in fair value relating to liabilities at fair value through profit or loss are charged to profit or loss as incurred.

2. Other financial liabilities: All liabilities, which have not been classified as in the previous category fall into this residual category. These liabilities are carried at amortised cost using the effective interest method. Trade and other payables are classified in this category. Items classified within current trade and other payables are not usually re-measured, as the obligation is usually known with a high degree of certainty and settlement is short-term.

2. Summary of significant accounting policies (cont'd)

Fair value measurement

Fair value is taken to be the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (that is, an exit price). It is a market-based measurement, not an entity-specific measurement. When measuring fair value, management uses the assumptions that market participants would use when pricing the asset or liability under current market conditions, including assumptions about risk. The entity's intention to hold an asset or to settle or otherwise fulfil a liability is not taken into account as relevant when measuring fair value. In making the fair value measurement, management determines the following: (a) the particular asset or liability being measured (these are identified and disclosed in the relevant notes below); (b) for a non-financial asset, the highest and best use of the asset and whether the asset is used in combination with other assets or on a stand-alone basis; (c) the market in which an orderly transaction would take place for the asset or liability; and (d) the appropriate valuation techniques to use when measuring fair value. The valuation techniques used maximise the use of relevant observable inputs and minimise unobservable inputs. These inputs are consistent with the inputs a market participant may use when pricing the asset or liability.

The fair value measurements and related disclosures categorise the inputs to valuation techniques used to measure fair value by using a fair value hierarchy of three levels. These are recurring fair value measurements unless stated otherwise in the relevant notes to the financial statements. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date. Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 3 inputs are unobservable inputs for the asset or liability. The level is measured on the basis of the lowest level input that is significant to the fair value measurement in its entirety. Transfers between levels of the fair value hierarchy are deemed to have occurred at the beginning of the reporting year. If a financial instrument measured at fair value has a bid price and an ask price, the price within the bid-ask spread or mid-market pricing that is most representative of fair value in the circumstances is used to measure fair value regardless of where the input is categorised within the fair value hierarchy. If there is no market, or the markets available are not active, the fair value is established by using an acceptable valuation technique.

The carrying values of current financial instruments approximate their fair values due to the short-term maturity of these instruments and the disclosures of fair value are not made when the carrying amount of current financial instruments is a reasonable approximation of the fair value. The fair values of non-current financial instruments may not be disclosed separately unless there are significant differences at the end of the reporting year and in the event the fair values are disclosed in the relevant notes to the financial statements.

Funds

Fund balances restricted by outside sources are so indicated and are distinguished from unrestricted funds allocated to specific purposes if any by action of the management. Externally restricted funds may only be utilised in accordance with the purposes established by the source of such funds or through the terms of an appeal and are in contrast with unrestricted funds over which management retains full control to use in achieving any of its institutional purposes. An expense resulting from the operating activities of a fund that is directly attributable to the fund is charged to that fund. Common expenses if any are allocated on a reasonable basis to the funds based on a method most suitable to that common expense unless impractical to do so.

2. Summary of significant accounting policies (cont'd)

Provisions

A liability or provision is recognised when there is a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. A provision is made using best estimates of the amount required in settlement and where the effect of the time value of money is material, the amount recognised is the present value of the expenditures expected to be required to settle the obligation using a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the obligation. The increase in the provision due to passage of time is recognised as interest expense. Changes in estimates are reflected in profit or loss in the period they occur.

Critical judgements, assumptions and estimation uncertainties

There were no critical judgements made in the process of applying the accounting policies that have the most significant effect on the amounts recognised in the financial statements. There were no key assumptions concerning the future, and other key sources of estimation uncertainty at the end of the reporting year, that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next reporting year.

3. Related party relationships and transactions

A related party includes the Council members and key management of the Society. It also includes an entity or person that directly or indirectly controls, is controlled by, or is under common or joint control with these persons; members of the key management personnel or close members of the family of any individual referred to herein and others who have the ability to control, jointly control or significantly influence by or for which significant voting power in such entity resides with, directly or indirectly, any such individual. Key management personnel include the CEO and the direct reporting senior officers.

The Council members, or people connected with them, have not received remuneration, or other benefits, from the Society or from institutions connected with the Society.

There is no claim by the Council members for services provided to the Society, either by reimbursement to the Council members or by providing the Council members with an allowance or by direct payment to a third party.

All Council members, chairman of sub-committees and staff members of the Society are required to read and understand the conflict of interest policy in place and make full disclosure of interests, relationships and holding that could potentially result in conflict of interests. When a conflict of interest situation arises, the members or staff shall abstain from participating in the discussion, decision making and voting on the matter.

3. Related party relationships and transactions (cont'd)

3A. Key management compensation:

	2015 $	2014 $
Salaries and other short-term employee benefits	1,162,982	876,091

Key management personnel comprise the senior managers and above. The council members did not receive any compensation during the year.

There were no transactions with a corporation in which the above key management personnel have an interest.

The number of top three executives of the Society in remuneration bands is as follows:

	2015 Number of executives	2014 Number of executives
Remuneration bands:		
$200,000 to $299,999	3	2
$100,000 to $199,999	–	1

4. Fund generating income and expenditure

In accordance with the Charities (Institutions of a Public Character) Regulations, the Society is required to disclose fund-raising appeals with gross receipts of more than $1 million.

	Income for General Fund $	Fund Generating Expenses for General Fund $	Net Fund Generating Income for General Fund $
2015			
Charity Run	1,564,912	406,978	1,157,934
2014			
Charity Run	1,183,063	368,736	814,327

5. Investment income

	2015 $	2014 $
Interest income	587,832	260,892

6. Employee benefits expense

	2015 $	2014 $
Short term employee benefits expense	5,451,364	4,480,940
Contributions to defined contribution plan	686,442	547,799
Total employee benefits expense	6,137,806	5,028,739

7. Items in the statement of financial activities

In addition to the charges and credits disclosed elsewhere in the notes to the financial statements, the statement of financial activities includes the following credits/(charges):

	2015 $	2014 $
Sponsorship income	250,000	250,000
Audit fees to the independent auditor	(28,890)	(28,890)
Other attestation fees to the independent auditor	(10,075)	(7,105)

8. Tax-exempt receipts

The Society enjoys a concessionary tax treatment whereby qualifying donors are granted 3 times (2014: 2.5 times) tax deduction for the donations made to the Society.

	2015 $	2014 $
The Society issued tax-exempt receipts for donations collected	13,170,081	14,297,117

9. Property, plant and equipment

	Freehold office premises $	Computers $	Furniture and fittings $	Motor vehicles $	Total $
Cost					
At 1 January 2014	2,973,988	373,137	623,629	91,020	4,061,774
Additions	–	48,792	311,911	100,000	460,703
Disposals	–	(105,092)	(25,205)	–	(130,297)
At 1 January 2015	2,973,988	316,837	910,335	191,020	4,392,180
Additions	–	129,628	1,352,766	–	1,482,394
Disposals	–	(37,264)	(105,107)	–	(142,371)
At 31 December 2015	2,973,988	409,201	2,157,994	191,020	5,732,203
Accumulated Depreciation					
At 1 January 2014	1,313,285	296,964	398,817	26,745	2,035,811
Depreciation for the year	21,163	50,327	93,242	10,230	174,962
Disposals	–	(104,949)	(19,981)	–	(124,930)
At 1 January 2015	1,334,448	242,342	472,078	36,975	2,085,843
Depreciation for the year	59,455	55,413	168,047	22,641	305,556
Disposals	–	(37,198)	(104,740)	–	(141,938)
At 31 December 2015	1,393,903	260,557	535,385	59,616	2,249,461
Carrying value:					
At 1 January 2014	1,660,703	76,173	224,812	64,275	2,025,963
At 1 January 2015	1,639,540	74,495	438,257	154,045	2,306,337
At 31 December 2015	1,580,085	148,644	1,622,609	131,404	3,482,742

9A. Property, plant and equipment (cont'd)

Fully depreciated plant and equipment still in use had a cost of $438,600 (2014: $461,461).

It is impractical to separately allocate the cost of the freehold property (strata title issued on 29 September 1972) to the portion relating to the freehold land.

10. Other financial assets, non-current

	2015 $	2014 $
Non-current		
Held-to-maturity investments at amortised cost (Level 1) (Note 10A)	22,379,925	8,000,000
Current		
Held-to-maturity investments at amortised cost (Level 1)	4,000,000	–
	26,379,925	8,000,000

10A. Held-to-maturity investments

	2015 $	2014 $
Movements during the year - at amortised cost:		
Amortised cost at beginning of the year	8,000,000	8,000,000
Additions at cost	18,379,925	–
Bonds maturing within one year	(4,000,000)	–
Amortised cost at end of the year	22,379,925	8,000,000
Balance is made up of:		
Statutory Board's bonds with fixed interest of 1.685% and maturing on 8 June 2016	–	3,000,000
Statutory Board's bonds with fixed interest of 1.950% and maturing on 22 September 2021	2,000,000	2,000,000
Statutory Board's bonds with fixed interest of 1.230% and maturing on 30 January 2018	2,000,000	2,000,000
Statutory Board's bonds with fixed interest of 1.165% and maturing on 26 July 2016	–	1,000,000
Statutory Board's bonds with fixed interest of 2.505% and maturing on 27 June 2024	487,500	–
Quoted bonds in corporation with fixed interest of 4.300% and maturing on 30 November 2018	533,500	–
Quoted bonds in corporation with fixed interest of 3.750% and maturing on 8 March 2019	528,500	–
Quoted bonds in corporation with fixed interest of 3.780% and maturing on 16 August 2019	1,048,400	–
Quoted bonds in corporation with fixed interest of 3.265% and maturing on 19 February 2020	1,338,125	–
Quoted bonds in corporation with fixed interest of 3.500% and maturing on 30 March 2020	2,148,000	–
Quoted bonds in corporation with fixed interest of 3.7325% and maturing on 9 April 2020	2,108,000	–
Quoted bonds in corporation with fixed interest of 3.100% and maturing on 12 October 2020	1,020,500	–
Quoted bonds in corporation with fixed interest of 4.000% and maturing on 3 February 2022	263,375	–

10. Other financial assets, non-current (cont'd)

10A. Held-to-maturity investments (cont'd)

	2015 $	2014 $
Balance is made up of: (cont'd)		
Quoted bonds in corporation with fixed interest of 4.000% and maturing on 14 February 2022	247,275	–
Quoted bonds in corporation with fixed interest of 3.700% and maturing on 29 August 2022	2,045,750	–
Quoted bonds in corporation with fixed interest of 2.363% and maturing on 5 October 2022	246,500	–
Quoted bonds in corporation with fixed interest of 3.750% and maturing on 8 April 2024	1,299,500	–
Quoted bonds in corporation with fixed interest of 3.072% and maturing on 11 June 2024	1,007,000	–
Quoted bonds in corporation with fixed interest of 3.480% and maturing on 6 August 2024	2,017,000	–
Quoted bonds in corporation with fixed interest of 3.800% and maturing on 28 August 2024	2,041,000	–
Balance at end of the year	22,379,925	8,000,000
Fair value at end of the year:		
Statutory Board's bonds with fixed interest of 1.685% and maturing on 8 June 2016	–	3,014,253
Statutory Board's bonds with fixed interest of 1.950% and maturing on 22 September 2021	1,931,780	1,904,022
Statutory Board's bonds with fixed interest of 1.230% and maturing on 30 January 2018	1,975,260	1,945,812
Statutory Board's bonds with fixed interest of 1.165% and maturing on 26 July 2016	–	995,419
Statutory Board's bonds with fixed interest of 2.505% and maturing on 27 June 2024	491,165	–
Quoted bonds in corporation with fixed interest of 4.300% and maturing on 30 November 2018	520,433	–
Quoted bonds in corporation with fixed interest of 3.750% and maturing on 8 March 2019	515,800	–
Quoted bonds in corporation with fixed interest of 3.780% and maturing on 16 August 2019	1,019,340	–
Quoted bonds in corporation with fixed interest of 3.265% and maturing on 19 February 2020	1,286,413	–
Quoted bonds in corporation with fixed interest of 3.500% and maturing on 30 March 2020	2,057,000	–
Quoted bonds in corporation with fixed interest of 3.7325% and maturing on 9 April 2020	2,039,000	–
Quoted bonds in corporation with fixed interest of 3.100% and maturing on 12 October 2020	998,570	–
Quoted bonds in corporation with fixed interest of 4.000% and maturing on 3 February 2022	258,105	–
Quoted bonds in corporation with fixed interest of 4.000% and maturing on 14 February 2022	246,076	–
Quoted bonds in corporation with fixed interest of 3.700% and maturing on 29 August 2022	2,015,150	–
Quoted bonds in corporation with fixed interest of 2.363% and maturing on 5 October 2022	243,158	–

10. Other financial assets, non-current (cont'd)

10A. Held-to-maturity investments (cont'd)

	2015 $	2014 $
Fair value at end of the year: (cont'd)		
Quoted bonds in corporation with fixed interest of 3.750% and maturing on 8 April 2024	1,288,994	–
Quoted bonds in corporation with fixed interest of 3.072% and maturing on 11 June 2024	999,040	–
Quoted bonds in corporation with fixed interest of 3.480% and maturing on 6 August 2024	2,003,500	–
Quoted bonds in corporation with fixed interest of 3.800% and maturing on 28 August 2024	2,006,460	–
Balance at end of the year	21,895,244	7,859,506

The fair values of quoted bonds are based on prices in an active market (Level 1) at the end of the reporting year.

11. Inventories

	2015 $	2014 $
Accessories and consumables	9,768	285
Changes in inventories (increase)/decrease	(9,483)	705

There are no inventories pledged as security for liabilities.

12. Other receivables

	2015 $	2014 $
Interest receivable	254,018	88,595
Ministry of Health	190,877	81,362
Singtel	250,000	250,000
TOTE Board	50,000	–
Other receivables (a)	692,158	1,062,939
	1,437,053	1,482,896

(a) Included in other receivables is an amount of $390,084 (2014: nil) receivable from Movember Group Pty Ltd in relation to funds generating activities. This amount is held by Movember Group Pty Ltd, and will be released to the Society upon utilisation of the funds received in previous reporting years. See Note 16B for the restricted fund balance.

13. Other assets

	2015 $	2014 $
Deposits to secure services	151,743	23,018
Prepayments	454,279	263,024
	606,022	286,042

14. Cash and cash equivalents

	2015 $	2014 $
Not restricted in use	26,093,977	44,494,540
Cash restricted under Community Silver Trust Grant (Note 16A)	4,121,494	3,585,175
Cash restricted under Movember Grant (Note 16B)	-	210,056
Restricted in use (Note 14A)	10,015,616	2,031,891
	40,231,087	50,321,662
Interest earning balances	35,838,508	37,594,473

The interest rates for the cash on interest earning accounts are between 0.05% and 1.65% (2014: 0.05% and 1.65%).

14A. Cash and cash equivalents in the statement of cash flows:

	2015 $	2014 $
Amount as shown above	40,231,087	50,321,662
Cash restricted under specific funds	(4,121,494)	(3,795,231)
Cash restricted in use over 3 months	(10,015,616)	(2,031,891)
Cash and cash equivalents for statement of cash flows purposes at end of the year	26,093,977	44,494,540

14B. Non cash transactions:

There were additions to certain assets under property, plant and equipment with a total cost of $ Nil (2014 : $100,000) that was received in kind.

15. Trade payables

	2015 $	2014 $
Outside parties and accrued liabilities	2,872,952	2,281,008

16. Other liabilities

	2015 $	2014 $
Deferred grants:		
Community Silver Trust Grant (Note 16A)	4,121,494	3,585,175
Movember Grant (Note 16B)	-	210,056
Deferred grants, total	4,121,494	3,795,231

16. Other liabilities (cont'd)

16A. Community Silver Trust Grant

	2015 $	2014 $
Incoming Resources		
Balance at beginning of the year	3,585,175	4,705,921
Grant received during the year	5,000,000	1,242,685
Utilised during the year	(4,463,681)	(2,363,431)
Balance at end of year	4,121,494	3,585,175
Expenditure		
Psychosocial team	613,214	438,186
Hospice homecare and support group expenses	1,864,228	1,925,245
Cancer Rehabilitation Centre expenses	1,986,239	-
	4,463,681	2,363,431

The SCS-CST Matching Fund ("CST") is a dollar-to-dollar donation matching grant provided by the government to enhance the services of voluntary welfare organisations in the intermediate and long-term care sector. One key objective of the CST is to encourage public donations from individuals, foundations and corporate establishments. With additional CST funds matched by the government, the Societies will be able to enhance capabilities and expand their capacities to improve quality of care and provide affordable step down care.

16B. Movember Grant

	2015 $	2014 $
Incoming Resources		
Balance at beginning of the year	210,056	210,056
Transfer to Restricted Fund during the year	(210,056)	–
Balance at end of year	–	210,056

The Movember Grant consists of grants received from Movember Group Pty Ltd. These are granted to the Society for the purpose of funding innovative research that builds powerful, collaborative teams that accelerates improved clinical tests and treatments for prostate and testicular cancer, and improved physical and mental health outcomes for men. The Society also aims to provide care for men with prostate or testicular cancer to be physically and mentally well.

The balance of $210,056 was transferred to Restricted Fund during the year as the funds will be fully channelled to the Survivorship Program which is in partnership with Movember Group Pty Ltd.

17. Fund account balances

(i) The Cancer Treatment Fund was established in 2005, with the objective to assist cancer patients that have financial difficulties.

(ii) The SCS-CST Matching Fund is for monies set aside by the Society for additional resources to enhance capabilities and provide value-added services to achieve affordable and higher quality care. These resources are further supplemented by the grant from the government (see Note 16A).

17. Fund account balances (cont'd)

(iii) Run for Hope Fund was established in 2006 to fund institutions in cancer research.

(iv) The RGS-Joan Chan Shu Fang Fund was established in 2006 to fund young cancer patients and support Raffles' Girls School curriculum.

(v) The Movember Fund consists of grants received from Movember Group Pty Ltd. These are granted to the Society for the purpose of raising awareness on male health issues.

Interest income has not been allocated to the respective funds as it is impracticable to do so.

18. Columnar presentation of statement of financial position

A large majority of the assets and liabilities are attributable to the General Fund. All the assets of the other funds are represented by cash balances. Accordingly the Society did not adopt a columnar presentation of its assets, liabilities and funds in the Statement of Financial Position as it was not meaningful.

19. Operating lease payment commitments – as lessee

At the end of the reporting year the total of future minimum lease payment commitments under non-cancellable operating leases are as follows:

	2015 $	2014 $
Not later than one year	584,913	16,339
Later than one year and not later than five years	2,157,616	–
Rental expense for the year	207,080	39,213

Operating lease payments are for rentals payable by the Society for certain office premises. The leases are negotiated for an average term of 2 years and are subject to an escalation clause but the amount of the rent increase is not to exceed a certain percentage.

20. Capital commitments

Estimated amounts committed at the end of the reporting year for future capital expenditure but not recognized in the financial statements are as follows:

	2015 $	2014 $
Commitments to purchase of equipment	519,038	87,848

21. Financial instruments: information on financial risks

21A. Cateogories of financial assets and liabilities

The following table categorises the carrying amount of financial assets and liabilities recorded at the end of the reporting year:

	2015 $	2014 $
Financial assets:		
Cash and bank balances	40,231,087	50,321,662
Held-to-maturity investments	26,379,925	8,000,000
Loans and receivables	1,437,053	1,482,896
	68,048,065	59,804,558
Financial liabilities:		
Trade and other payables at amortised cost	2,872,952	2,281,008
	2,872,952	2,281,008

Further quantitative disclosures are included throughout these financial statements.

21B. Financial risk management

The main purpose for holding or issuing financial instruments is to raise and manage the finances for the entity's operating, investing and financing activities. There are exposures to the financial risks on the financial instruments such as credit risk, liquidity risk and market risk comprising interest rate, currency risk and price risk exposures. Management has certain practices for the management of financial risks. The guidelines set up the short and long term objectives and action to be taken in order to manage the financial risks. The guidelines include the following:

1. All financial risk management activities are carried out and monitored by senior management staff.
2. All financial risk management activities are carried out following good market practices.
3. When appropriate may consider investing in shares or similar instruments.
4. When appropriate enter into derivatives or any other similar instruments solely for hedging purposes.

There have been no changes to the exposures to risk; the objectives, policies and processes for managing the risk and the methods used to measure the risk.

21C. Fair value of financial instruments

The analyses of financial instruments that are measured subsequent to initial recognition at fair value, grouped into Levels 1 to 3 are disclosed in the relevant notes to the financial statements. These include both the significant financial instruments stated at amortised cost and at fair value in the statement of financial position. The carrying values of current financial instruments approximate their fair values due to the short-term maturity of these instruments and the disclosures of fair value are not made when the carrying amount of current financial instruments is a reasonable approximation of the fair value.

21. Financial instruments: information on financial risks (cont'd)

21D. Credit risk on financial assets

Financial assets that are potentially subject to concentrations of credit risk and failures by counterparties to discharge their obligations in full or in a timely manner consist principally of cash balances with banks, cash equivalents, receivables and certain other financial assets. The maximum exposure to credit risk is: the total of the fair value of the financial assets; the maximum amount the entity could have to pay if the guarantee is called on; and the full amount of any payable commitments at the end of the reporting year. Credit risk on cash balances with banks and any other financial instruments is limited because the counter-parties are entities with acceptable credit ratings. Credit risk on other financial assets is limited because the other parties are entities with acceptable credit ratings. For credit risk on receivables an ongoing credit evaluation is performed on the financial condition of the debtors and a loss from impairment is recognised in profit or loss. There is no significant concentration of credit risk on receivables, as the exposure is spread over a large number of counter-parties and debtors unless otherwise disclosed in the notes to the financial statements below.

Note 14 discloses the maturity of the cash and cash equivalents balances.

Other receivables are normally with no fixed terms and therefore there is no maturity (Note 12).

Concentration of other receivables: These are identified in Note 12.

21E. Liquidity risk – financial liabilities maturity analysis

The liquidity risk is managed on the basis of expected maturity dates of the financial liabilities. All financial liabilities of the Society are due within one year. The average credit period taken to settle trade payables is about 30 days (2014: 30 days). The Society has sufficient cash balances to support the commitments for the existing liabilities. The Society does not have any borrowings.

21F. Interest rate risk

The following table analyses the breakdown by type of interest rate:

	2015 $	2014 $
Financial assets:		
Fixed rate	62,218,433	45,594,473
Non-interest bearing	5,829,632	14,210,085
At end of year	68,048,065	59,804,558

The interest rates where applicable are disclosed in the respective notes.

Sensitivity analysis: The effect on statement of financial activities is not significant.

22. Changes and adoption of financial reporting standards

For the current reporting year new or revised Singapore Financial Reporting Standards and the related Interpretations to FRS ("INT FRS") were issued by the Singapore Accounting Standards Council. Those applicable to the reporting entity are listed below. These applicable new or revised standards did not require any modification of the measurement methods or the presentation in the financial statements.

FRS No.	Title
FRS 1	Amendments to FRS 1: Disclosure Initiative (early application)
FRS 19	Amendments To FRS 19: Defined Benefit Plans: Employee Contributions
Various	Improvements to FRSs (Issued in January 2014). Relating to FRS 113 Fair Value Measurement FRS 16 Property, Plant and Equipment
Various	Improvements to FRSs (Issued in February 2014). Relating to FRS 113 Fair Value Measurement

23. New or amended standards in issue but not yet effective

For the future reporting years new or revised Singapore Financial Reporting Standards and the related Interpretations to FRS ("INT FRS") were issued by the Singapore Accounting Standards Council and these will only be effective for future reporting years. Those applicable to the reporting entity for future reporting years are listed below. The transfer to the applicable new or revised standards from the effective dates is not expected to result in material adjustments to the financial position, results of operations, or cash flows for the following year.

FRS No.	Title	Effective date for periods beginning on or after
FRS 1	Amendments to FRS 1: Disclosure Initiative	1 Jan 2016
FRS 16 and 38	Amendments to FRS 16 and FRS 38: Clarification of Acceptable Methods of Depreciation and Amortisation	1 Jan 2016
FRS 109	Financial Instruments	1 Jan 2018

SINGAPORE CANCER SOCIETY (UEN: S65SS0033F)
Statement of Financial Activities – Supplementary Schedules
For the Reporting Year Ended 31 December 2015

2015	Unrestricted funds				Restricted funds				
	General Fund	Cancer Treatment Fund	SCS-CST Matching Fund	Sub-Total	Run For Hope Fund	RGS-Joan Chan Shu Fang Fund	Movember Fund	Sub-Total	Total
	$	$	$	$	$	$	$	$	$
INCOME									
Voluntary income									
Outright donations	2,237,707	-	-	2,237,707	-	-	-	-	**2,237,707**
Direct debit donors Programme	10,418,658	-	-	10,418,658	-	-	-	-	**10,418,658**
Grants	4,463,681	-	-	4,463,681	-	-	-	-	**4,463,681**
MOH subvention	973,019	-	-	973,019	-	-	-	-	**973,019**
	18,093,065	-	-	18,093,065	-	-	-	-	**18,093,065**
Charitable income									
Membership fees	1,365	-	-	1,365	-	-	-	-	**1,365**
Registration Fees	140	-	-	140	-	-	-	-	**140**
	1,505	-	-	1,505	-	-	-	-	**1,505**
Funds generating activities									
Projects/events	2,699,217	-	-	2,699,217	-	-	855,150	855,150	**3,554,367**
Race against Cancer	1,564,912	-	-	1,564,912	-	-	-	-	**1,564,912**
Direct mail appeals	28,818	-	-	28,818	-	-	-	-	**28,818**
	4,292,947	-	-	4,292,947	-	-	855,150	855,150	**5,148,097**
Investment income									
Interest income	587,832	-	-	587,832	-	-	-	-	**587,832**
	587,832	-	-	587,832	-	-	-	-	**587,832**
Others									
Sundry income	1,113,565	-	-	1,113,565	7,739	-	-	7,739	**1,121,304**
Total income	24,088,914	-	-	24,088,914	7,739	-	855,150	862,889	**24,951,803**

SINGAPORE CANCER SOCIETY (UEN: S65SS0033F)

2015	Unrestricted funds				Restricted funds				
	General Fund $	Cancer Treatment Fund $	SCS-CST Matching Fund $	Sub-Total $	Run For Hope Fund $	RGS-Joan Chan Shu Fang Fund $	Movember Fund $	Sub-Total $	Total $
EXPENSES									
Costs of generating voluntary income: Fund raising									
Website upgrade & Maintenance	37,290	-	-	37,290	-	-	-	-	37,290
Staff Cost	209,320	-	-	209,320	-	-	-	-	209,320
Depreciation	447	-	-	447	-	-	-	-	447
Staff Meeting & Refreshment	9	-	-	9	-	-	-	-	9
Repair & maintenance on equipments	891	-	-	891	-	-	-	-	891
Corporate Premium	4,429	-	-	4,429	-	-	-	-	4,429
Advertisement	68,095	-	-	68,095	-	-	-	-	68,095
Newsletter	9,146	-	-	9,146	-	-	-	-	9,146
Transport and traveling	674	-	-	674	-	-	-	-	674
Printing and stationery	239	-	-	239	-	-	-	-	239
Postage and courier	602	-	-	602	-	-	-	-	602
Newspapers and Periodical	639	-	-	639	-	-	-	-	639
Staff training	1,949	-	-	1,949	-	-	-	-	1,949
Staff welfare	20	-	-	20	-	-	-	-	20
Publicity & rebranding	20,371	-	-	20,371	-	-	-	-	20,371
Share Service Cost	(159,095)	-	-	(159,095)	-	-	-	-	(159,095)
Direct debit donors programme	533,648	-	-	533,648	-	-	-	-	533,648
	728,674	-	-	728,674	-	-	-	-	728,674

SINGAPORE CANCER SOCIETY (UEN: S65SS0033F)

2015	Unrestricted funds				Restricted funds				
	General Fund	Cancer Treatment Fund	SCS-CST Matching Fund	Sub-Total	Run For Hope Fund	RGS-Joan Chan Shu Fang Fund	Movember Fund	Sub-Total	Total
	$	$	$	$	$	$	$	$	$
EXPENSES (cont'd)									
Costs of charitable activities: Cancer screening, public education and research									
Staff costs	1,098,593	-	-	1,098,593	-	-	-	-	**1,098,593**
Forum expenses	305,386	-	-	305,386	-	-	-	-	**305,386**
Education promotion of screening services		-	-		-	-	-	-	
Expenses	16,735			16,735					**16,735**
Cancer research		-	-		-	-	-	-	
expenses	259,911			259,911					**259,911**
Screening expenses	1,057,576	-	-	1,057,576	-	-	-	-	**1,057,576**
Mammogram	203,975	-	-	203,975	-	-	-	-	**203,975**
Mammogram – CHAS	84,263	-	-	84,263	-	-	-	-	**84,263**
FIT 50 Program	445,856	-	-	445,856	-	-	-	-	**445,856**
Master Agency Retainer		-	-		-	-	-	-	
Fee	77,040			77,040					**77,040**
GP Symposium	7,788	-	-	7,788	-	-	-	-	**7,788**
Maintenance of clinic	10,231	-	-	10,231	-	-	-	-	**10,231**
Repair & maintenance		-	-		-	-	-	-	
on premises	7,032			7,032					**7,032**
Depreciation	61,502	-	-	61,502	-	-	-	-	**61,502**
Utilities	2,470	-	-	2,470	-	-	-	-	**2,470**
Transport and traveling	8,743	-	-	8,743	-	-	-	-	**8,743**
Repair and maintenance		-	-		-	-	-	-	
on equipment	2,110			2,110					**2,110**
Printing and stationery	2,836	-	-	2,836	-	-	-	-	**2,836**
Postage and courier	5,750	-	-	5,750	-	-	-	-	**5,750**
Refreshment	1,291	-	-	1,291	-	-	-	-	**1,291**
Collateral and Other Exp	45,829	-	-	45,829	-	-	-	-	**45,829**
Share Service Cost	334,172	-	-	334,172	-	-	-	-	**334,172**
Staff training	1,919	-	-	1,919	-	-	-	-	**1,919**
Staff welfare	1,080	-	-	1,080	-	-	-	-	**1,080**
	4,042,088	-	-	4,042,088	-	-	-	-	**4,042,088**

2015	Unrestricted funds				Restricted funds				
	General Fund $	Cancer Treatment Fund $	SCS-CST Matching Fund $	Sub-Total $	Run For Hope Fund $	RGS-Joan Chan Shu Fang Fund $	Movember Fund $	Sub-Total $	Total $
EXPENSES (cont'd)									
Costs of charitable activities: Welfare services									
Staff costs	1,402,400	-	-	1,402,400	-	-	-	-	1,402,400
Cancer treatment subsidies	623,976	939,572	-	1,563,548	-	-	-	-	1,563,548
Welfare aid to cancer Patients	1,141,777	-	-	1,141,777	-	-	-	-	1,141,777
Cancer Care Fund	585,000	-	-	585,000	-	-	-	-	585,000
Medical supplies	43,150	-	-	43,150	-	-	-	-	43,150
Milk feeds expenses	307,336	-	-	307,336	-	-	-	-	307,336
Stoma bags expenses	144,623	-	-	144,623	-	-	-	-	144,623
Support Group	15,628	-	-	15,628	-	-	-	-	15,628
PCa Survivorship Program	-	-	-	-	-	-	59,764	59,764	59,764
Rental charges	19,607	-	-	19,607	-	-	-	-	19,607
Repair & maintenance on premises	7,025	-	-	7,025	-	-	-	-	7,025
Repair & maintenance on equipments	2,102	-	-	2,102	-	-	-	-	2,102
Utilities	2,470	-	-	2,470	-	-	-	-	2,470
Depreciation	16,846	-	-	16,846	-	-	-	-	16,846
Transport and traveling	29,436	-	-	29,436	-	-	-	-	29,436
Hospital transport	43,288	-	-	43,288	-	-	-	-	43,288
Printing and stationery	1,787	-	-	1,787	-	-	-	-	1,787
Postage and courier	12,732	-	-	12,732	-	-	-	-	12,732
Refreshment	1,529	-	-	1,529	-	-	-	-	1,529
General expenses	362	-	-	362	-	--	-	-	362
Other welfare expense	92,582	-	-	92,582	-	-	-	-	92,582
Share Service Cost	726,969	-	-	726,969	-	-	-	-	726,969
Staff welfare	2,054	-	-	2,054	-	-	-	-	2,054
Staff training expenses	43,637	-	-	43,637	-	-	-	-	43,637
	5,266,316	939,572	-	6,205,888	-	-	59,764	59,764	6,265,652

2015	Unrestricted funds				Restricted funds				
	General Fund	Cancer Treatment Fund	SCS-CST Matching Fund	Sub-Total	Run For Hope Fund	RGS-Joan Chan Shu Fang Fund	Movember Fund	Sub-Total	Total
	$	$	$	$	$	$	$	$	$
EXPENSES (cont'd)									
Costs of charitable activities: Hospice homecare and support group expenses									
Staff costs	1,425,629	-	-	1,425,629	-	-	-	-	1,425,629
Other support group Expenses	25,196	-	-	25,196	-	-	-	-	25,196
General expenses	10,000	-	-	10,000	-	-	-	-	10,000
Repair & maintenance on equipments	1,592	-	-	1,592	-	-	-	-	1,592
Depreciation	19,585	-	-	19,585	-	-	-	-	19,585
General insurance	2,358	-	-	2,358	-	-	-	-	2,358
Hospice homecare expenses	9,917	-	-	9,917	-	-	-	-	9,917
Medical supplies	30,821	-	-	30,821	-	-	-	-	30,821
Transport and traveling	71,012	-	-	71,012	-	-	-	-	71,012
Printing and stationery	627	-	-	627	-	-	-	-	627
Postage and courier	8,636	-	-	8,636	-	-	-	-	8,636
Refreshment	49	-	-	49	-	-	-	-	49
Staff welfare	2,311	-	-	2,311	-	-	-	-	2,311
Share Service Cost	429,440	-	-	429,440	-	-	-	-	429,440
Staff training expenses	6,677	-	-	6,677	-	-	-	-	6,677
	2,043,850	-	-	2,043,850	-	-	-	-	2,043,850

SINGAPORE CANCER SOCIETY (UEN: S65SS0033F)

2015	Unrestricted funds				Restricted funds				
	General Fund	Cancer Treatment Fund	SCS-CST Matching Fund	Sub-Total	Run For Hope Fund	RGS-Joan Chan Shu Fang Fund	Movember Fund	Sub-Total	Total
	$	$	$	$	$	$	$	$	$
EXPENSES (cont'd)									
Costs of fund generating activities									
Staff costs	392,361	-	-	392,361	-	-	-	-	392,361
Audit fee	1,484	-	-	1,484	-	-	-	-	1,484
Third party event	1,559	-	-	1,559	-	-	-	-	1,559
Movember	-	-	-	-	-	-	141,258	141,258	141,258
Direct Debit Donors Programme	653,618	-	-	653,618	-	-	-	-	653,618
Race Against Cancer	406,978	-	-	406,978	-	-	-	-	406,978
Volunteers' Programme	47,921	-	-	47,921	-	-	-	-	47,921
Other Fund generating expenses	5,729	-	-	5,729	-	-	-	-	5,729
Direct Mailer	2,219	-	-	2,219	-	-	-	-	2,219
Birthday Bash & CCK	155,446	-	-	155,446	-	-	-	-	155,446
Transport and traveling	3,452	-	-	3,452	-	-	-	-	3,452
Depreciation	152	-	-	152	-	-	-	-	152
Repair & maintenance on equipment	2	-	-	2	-	-	-	-	2
Printing and stationery	378	-	-	378	-	-	-	-	378
Postage and courier	2,410	-	-	2,410	-	-	-	-	2,410
Outright donation expenses	28,182	-	-	28,182	-	-	-	-	28,182
Staff Welfare	143	-	-	143	-	-	-	-	143
Staff Training	642	-	-	642	-	-	-	-	642
Staff meeting & refreshment	14	-	-	14	-	-	-	-	14
Bank charges	10	-	-	10	-	-	-	-	10
Share Service Cost	136,796	-	-	136,796	-	-	-	-	136,796
	1,839,496	-	-	1,839,496	-	-	141,258	141,258	1,980,754

2015	Unrestricted funds				Restricted funds				
	General Fund $	Cancer Treatment ndFu $	SCS-CST Matching Fund $	Sub-Total $	Run For Hope Fund $	RGS-Joan Chan Shu Fang Fund $	Movember Fund $	Sub-Total $	**Total $**
EXPENSES (cont'd)									
Costs of charitable activities: Cancer Rehab									
Staff costs	223,024	-	-	223,024	-	-	-	-	**223,024**
Audit & Professional fee	60	-	-	60	-	-	-	-	**60**
Transport and traveling	3,391	-	-	3,391	-	-	-	-	**3,391**
Depreciation	42,010	-	-	42,010	-	-	-	-	**42,010**
Medical & Oth Supplies	27,172	-	-	27,172	-	-	-	-	**27,172**
Project & Initiatives	16,945	-	-	16,945	-	-	-	-	**16,945**
Repair & maintenance on premises	58,531	-	-	58,531	-	-	-	-	**58,531**
Repair & maintenance on equipment	54,717	-	-	54,717	-	-	-	-	**54,717**
Rental charges	167,867	-	-	167,867	-	-	-	-	**167,867**
Printing and stationery	1,123	-	-	1,123	-	-	-	-	**1,123**
Postage and courier	14,491	-	-	14,491	-	-	-	-	**14,491**
Utilities	5,121	-	-	5,121	-	-	-	-	**5,121**
Other expenses	8,674	-	-	8,674	-	-	-	-	**8,674**
Staff Welfare	177	-	-	177	-	-	-	-	**177**
Staff Training	62	-	-	62	-	-	-	-	**62**
Staff meeting & refreshment	217	-	-	217	-	-	-	-	**217**
Share Service Cost	145,834	-	-	145,834	-	-	-	-	**145,834**
	769,416	-	-	769,416	-	-	-	-	**769,416**

SINGAPORE CANCER SOCIETY (UEN: S65SS0033F)

2015	Unrestricted funds				Restricted funds				
	General Fund	Cancer Treatment Fund	SCS-CST Matching Fund	Sub-Total	Run For Hope Fund	RGS-Joan Chan Shu Fang Fund	Movember Fund	Sub-Total	Total
	$	$		$		$	$	$	$
EXPENSES (cont'd)									
Administrative costs									
Staff costs	1,243,539	-	-	1,243,539	-	-	-	-	**1,243,539**
Audit fee	57,359	-	-	57,359	-	-	-	-	**57,359**
Repair and maintenance	169,937	-	-	169,937	-	-	-	-	**169,937**
Share Service Cost	(1,614,114)	-	-	(1,614,114)	-	-	-	-	**(1,614,114)**
Depreciation	165,014	-	-	165,014	-	-	-	-	**165,014**
Refreshments	10,412	-	-	10,412	-	-	-	-	**10,412**
General expenses	125	-	-	125	-	-	-	-	**125**
Bank charges	1,801	-	-	1,801	-	-	-	-	**1,801**
Transport and traveling	7,244	-	-	7,244	-	-	-	-	**7,244**
Printing and stationery	29,788	-	-	29,788	-	-	-	-	**29,788**
Utilities	30,208	-	-	30,208	-	-	-	-	**30,208**
Insurance	24,727	-	-	24,727	-	-	-	-	**24,727**
Other expenses	65	-	-	65	-	-	-	-	**65**
Postage and courier	31,894	-	-	31,894	-	-	-	-	**31,894**
Staff welfare	52,208	-	-	52,208	-	-	-	-	**52,208**
Staff training	8,003	-	-	8,003	-	-	-	-	**8,003**
Staff insurance	71,991	-	-	71,991	-	-	-	-	**71,991**
	290,201	-	-	290,201	-	-	-	-	**290,201**
Total expenses	14,980,041	939,572	-	15,919,613	-	-	201,022	201,022	**16,120,635**
Surplus/(deficit) for the reporting year	9,108,873	(939,572)	-	8,169,301	7,739	-	654,128	661,867	**8,831,168**

SINGAPORE CANCER SOCIETY (UEN: S65SS0033F)

Statement of Financial Activities – Supplementary Schedules
For the Reporting Year Ended 31 December 2015

2014	Unrestricted Funds					Restricted funds					
	General Fund	Cancer Treatment Fund	Cervical Cancer Prevention Fund	SCS-CST Matching Fund	Sub-Total	Run For Hope Fund	RGS-Joan Chan Shu Fang Fund	Koh Soh Eng Fund	Movember Fund	Sub-Total	Total
	$	$	$	$	$	$	$	$	$	$	$
INCOME											
Voluntary income											
Outright donations	1,708,090	32,720	4,000	–	1,744,810	–	5,623	(32,720)	–	(27,097)	**1,717,713**
Direct debit donors programme	12,247,897	–	–	–	12,247,897	–	–	–	–	–	**12,247,897**
Grants	2,363,431	–	–	–	2,363,431	–	–	–	–	–	**2,363,431**
MOH subvention	499,052	–	–	–	499,052	–	–	–	–	–	**499,052**
	16,818,470	32,720	4,000	–	16,855,190	–	5,623	(32,720)	–	(27,097)	**16,828,093**
Charitable income											
Membership fees	958	–	–	–	958	–	–	–	–	–	**958**
	958	–	–	–	958	–	–	–	–	–	**958**
Funds generating activities											
Projects / events	1,618,209	–	–	–	1,618,209	–	–	–	783,280	783,280	**2,401,489**
Race against Cancer	1,183,063	–	–	–	1,183,063	–	–	–	–	–	**1,183,063**
Direct mail appeals	158,669	–	–	–	158,669	–	–	–	–	–	**158,669**
	2,959,941	–	–	–	2,959,941	–	–	–	783,280	783,280	**3,743,221**
Investment income											
Interest income	260,892	–	–	–	260,892	–	–	–	–	–	**260,892**
	260,892	–	–	–	260,892	–	–	–	–	–	**260,892**
Others											
Sundry income	560,318	–	–	–	560,318	37,921	–	–	–	37,921	**598,239**
Total income	20,600,579	32,720	4,000	–	20,637,299	37,921	5,623	(32,720)	783,280	794,104	**21,431,403**

SINGAPORE CANCER SOCIETY (UEN: S65SS0033F)

2014	Unrestricted funds					Restricted funds					
	General Fund $	Cancer Treatment Fund $	Cervical Cancer Prevention Fund $	SCS-CST Matching Fund $	Sub-Total $	Run For Hope Fund $	RGS-Joan Chan Shu Fang Fund $	Koh Soh Eng Fund $	Movember Fund $	Sub-Total $	Total $
EXPENSES											
Costs of generating voluntary income: Fund raising											
Website upgrade & Maintenance	1,341	–	–	–	1,341	–	–	–	–	–	1,341
Staff Cost	45,300	–	–	–	45,300	–	–	–	–	–	45,300
Depreciation	3,186	–	–	–	3,186	–	–	–	–	–	3,186
General expenses	37	–	–	–	37	–	–	–	–	–	37
General insurance	713	–	–	–	713	–	–	–	–	–	713
Staff Meeting & Refreshment	235	–	–	–	235	–	–	–	–	–	235
Rental Charges	1,238	–	–	–	1,238	–	–	–	–	–	1,238
Repair & maintenance on premises	2,125	–	–	–	2,125	–	–	–	–	–	2,125
Repair & maintenance on equipments	540	–	–	–	540	–	–	–	–	–	540
Utilities	1,249	–	–	–	1,249	–	–	–	–	–	1,249
Corporate Premium	3,959	–	–	–	3,959	–	–	–	–	–	3,959
Advertisement	85,090	–	–	–	85,090	–	–	–	–	–	85,090
Newsletter	52,595	–	–	–	52,595	–	–	–	–	–	52,595
Transport and traveling	305	–	–	–	305	–	–	–	–	–	305
Printing and stationery	1,085	–	–	–	1,085	–	–	–	–	–	1,085
Postage and courier	1,919	–	–	–	1,919	–	–	–	–	–	1,919
Newspapers and Periodical	19	–	–	–	19	–	–	–	–	–	19
Staff training	673	–	–	–	673	–	–	–	–	–	673
Staff insurance/workmen compensation	1,803	–	–	–	1,803	–	–	–	–	–	1,803
Staff welfare	1,635	–	–	–	1,635	–	–	–	–	–	1,635
Publicity & rebranding	21,085	–	–	–	21,085	–	–	–	–	–	21,085
Other expenses	2,041	–	–	–	2,041	–	–	–	–	–	2,041
Audit fee	1,439	–	–	–	1,439	–	–	–	–	–	1,439
Direct debit donors programme	1,359,458	–	–	–	1,359,458	–	–	–	–	–	1,359,458
	1,589,070	–	–	–	1,589,070	–	–	–	–	–	1,589,070

SINGAPORE CANCER SOCIETY (UEN: S65SS0033F)

2014

	Unrestricted funds					Restricted funds					
	General Fund $	Cancer Treatment Fund $	Cervical Cancer Prevention Fund $	SCS-CST Matching Fund $	Sub-Total $	Run For Hope Fund $	RGS-Joan Chan Shu Fang Fund $	Koh Soh Eng Fund $	Movember Fund $	Sub-Total $	Total $
EXPENSES (cont'd)											
Costs of charitable activities: Cancer screening, public education and research											
Staff costs	1,193,431	–	–	–	1,193,431	–	–	–	–	–	1,193,431
Forum expenses	246,490	–	53,554	–	300,044	–	–	–	–	–	300,044
Education promotion of screening services Expenses	20,355	–	–	–	20,355	–	–	–	–	–	20,355
Cancer research expenses	522,975	–	–	–	522,975	–	–	–	–	–	522,975
Screening expenses	934,470	–	30,746	–	965,216	–	–	–	–	–	965,216
Mammogram	53,205	–	–	–	53,205	–	–	–	–	–	53,205
Maintenance of clinic	5,859	–	–	–	5,859	–	–	–	–	–	5,859
Repair & maintenance on premises	19,065	–	–	–	19,065	–	–	–	–	–	19,065
Depreciation	54,737	–	–	–	54,737	–	–	–	–	–	54,737
Utilities	7,079	–	–	–	7,079	–	–	–	–	–	7,079
General insurance	4,041	–	–	–	4,041	–	–	–	–	–	4,041
Transport and traveling	9,018	–	–	–	9,018	–	–	–	–	–	9,018
Repair and maintenance on equipment	3,139	–	–	–	3,139	–	–	–	–	–	3,139
Printing and stationery	9,275	–	–	–	9,275	–	–	–	–	–	9,275
Postage and courier	11,307	–	–	–	11,307	–	–	–	–	–	11,307
Refreshment	1,442	–	–	–	1,442	–	–	–	–	–	1,442
General expenses	208	–	–	–	208	–	–	–	–	–	208
Audit fee	8,153	–	–	–	8,153	–	–	–	–	–	8,153
Collateral and Other Exp	82,534	–	–	–	82,534	–	–	–	–	–	82,534
Staff insurance/workmen compensation	10,216	–	–	–	10,216	–	–	–	–	–	10,216
Staff training	8,268	–	–	–	8,268	–	–	–	–	–	8,268
Staff welfare	9,982	–	–	–	9,982	–	–	–	–	–	9,982
	3,215,249	–	84,300	–	3,299,549	–	–	–	–	–	3,299,549

SINGAPORE CANCER SOCIETY (UEN: S65SS0033F)

2014	Unrestricted funds					Restricted funds					
	General Fund $	Cancer Treatment Fund $	Cervical Cancer Prevention Fund $	SCS-CST Matching Fund $	Sub-Total $	Run For Hope Fund $	RGS-Joan Chan Shu Fang Fund $	Koh Soh Eng Fund $	Movember Fund $	Sub-Total $	Total $
EXPENSES (cont'd)											
Costs of charitable activities: Welfare services											
Staff costs	1,643,330	–	–	–	1,643,330	–	–	–	–	–	1,643,330
Cancer treatment subsidies	1,220,420	–	–	–	1,220,420	–	5,417	–	–	5,417	1,225,837
Welfare aid to cancer Patients	726,957	–	–	–	726,957	–	–	–	–	–	726,957
Medical supplies	14,656	–	–	–	14,656	–	–	–	–	–	14,656
Milk feeds expenses	195,579	–	–	–	195,579	–	–	–	–	–	195,579
Stoma bags expenses	95,219	–	–	–	95,219	–	–	–	–	–	95,219
Support Group	12,614	–	–	–	12,614	–	–	–	–	–	12,614
Rental charges	12,383	–	–	–	12,383	–	–	–	–	–	12,383
Repair & maintenance on premises	21,247	–	–	–	21,247	–	–	–	–	–	21,247
Repair & maintenance on equipments	5,468	–	–	–	5,468	–	–	–	–	–	5,468
Utilities	12,492	–	–	–	12,492	–	–	–	–	–	12,492
Depreciation	49,521	–	–	–	49,521	–	–	–	–	–	49,521
General insurance	7,132	–	–	–	7,132	–	–	–	–	–	7,132
Transport and traveling	22,104	–	–	–	22,104	–	–	–	–	–	22,104
Hospital transport	25,473	–	–	–	25,473	–	–	–	–	–	25,473
Printing and stationery	13,037	–	–	–	13,037	–	–	–	–	–	13,037
Postage and courier	24,847	–	–	–	24,847	–	–	–	–	–	24,847
Refreshment	2,517	–	–	–	2,517	–	–	–	–	–	2,517
General expenses	730	–	–	–	730	–	–	–	–	–	730
Other welfare expense	116,924	–	–	–	116,924	–	–	–	–	–	116,924
Staff insurance	18,028	–	–	–	18,028	–	–	–	–	–	18,028
Staff welfare	17,703	–	–	–	17,703	–	–	–	–	–	17,703
Staff training expenses	37,706	–	–	–	37,706	–	–	–	–	–	37,706
	4,296,087	–	–	–	4,296,087	–	5,417	–	–	5,417	4,301,504

2014	Unrestricted funds					Restricted funds					
	General Fund	Cancer Treatment Fund	Cervical Cancer Prevention Fund	SCS-CST Matching Fund	Sub-Total	Run For Hope Fund	RGS-Joan Chan Shu Fang Fund	Koh Soh Eng Fund	Movember Fund	Sub-Total	Total
	$	$	$	$	$	$	$	$	$	$	$
EXPENSES (cont'd)											
Costs of charitable activities: Hospice homecare and support group expenses											
Staff costs	1,380,257	–	–	–	1,380,257	–	–	–	–	–	1,380,257
Other support group Expenses	67,537	–	–	–	67,537	–	–	–	–	–	67,537
General expenses	1,634	–	–	–	1,634	–	–	–	–	–	1,634
Repair & maintenance on premises	14,164	–	–	–	14,164	–	–	–	–	–	14,164
Repair & maintenance on equipments	3,630	–	–	–	3,630	–	–	–	–	–	3,630
Depreciation	38,820	–	–	–	38,820	–	–	–	–	–	38,820
Utilities	8,328	–	–	–	8,328	–	–	–	–	–	8,328
General insurance	4,754	–	–	–	4,754	–	–	–	–	–	4,754
Hospice homecare expenses	21,729	–	–	–	21,729	–	–	–	–	–	21,729
Medical supplies	14,719	–	–	–	14,719	–	–	–	–	–	14,719
Transport and traveling	44,972	–	–	–	44,972	–	–	–	–	–	44,972
Printing and stationery	8,251	–	–	–	8,251	–	–	–	–	–	8,251
Postage and courier	18,730	–	–	–	18,730	–	–	–	–	–	18,730
Refreshment	1,857	–	–	–	1,857	–	–	–	–	–	1,857
Staff welfare	14,738	–	–	–	14,738	–	–	–	–	–	14,738
Staff insurance	24,301	–	–	–	24,301	–	–	–	–	–	24,301
Staff training expenses	23,846	–	–	–	23,846	–	–	–	–	–	23,846
	1,692,267	–	–	–	1,692,267	–	–	–	–	–	1,692,267

SINGAPORE CANCER SOCIETY (UEN: S65SS0033F)

2014	Unrestricted funds					Restricted funds					
	General Fund	Cancer Treatment Fund	Cervical Cancer Prevention Fund	SCS-CST Matching Fund	Sub-Total	Run For Hope Fund	RGS-Joan Chan Shu Fang Fund	Koh Soh Eng Fund	Movember Fund	Sub-Total	Total
	$	$	$	$	$	$	$	$	$	$	$
EXPENSES (cont'd)											
Costs of fund generating activities											
Staff costs	389,415	–	–	–	389,415	–	–	–	–	–	389,415
Audit fee	4,316	–	–	–	4,316	–	–	–	–	–	4,316
Other Expenses	48,807	-	-	-	48,807	-	-	-	-	-	48,807
Third party event	88	–	–	–	88	–	–	–	–	–	88
Direct debit donors programme	621,403	-	-	-	621,403	-	-	-	-	-	621,403
Donor appreciation	397	-	-	-	397	-	-	-	-	-	397
Merchandise expenses	13,834	-	-	-	13,834	-	-	-	-	-	13,834
Movember	(942)	–	–	–	(942)	–	–	–	320,628	320,628	319,686
Daffodil day	360	–	–	–	360	–	–	–	–	–	360
Charity run	368,736	–	–	–	368,736	–	–	–	–	–	368,736
DM - SP insert	3,642	–	–	–	3,642	–	–	–	–	–	3,642
Transport and traveling	3,180	–	–	–	3,180	–	–	–	–	–	3,180
Depreciation	11,708	–	–	–	11,708	–	–	–	–	–	11,708
General expenses	110	–	–	–	110	–	–	–	–	–	110
General insurance	2,139	–	–	–	2,139	–	–	–	–	–	2,139
Repair & maintenance on premises	6,374	–	–	–	6,374	–	–	–	–	–	6,374
Repair & maintenance on equipment	2,829	–	–	–	2,829	–	–	–	–	–	2,829
Rental charges	826	-	-	-	826	-	-	-	-	-	826
Printing and stationery	3,864	–	–	–	3,864	–	–	–	–	–	3,864
Postage and courier	8,705	–	–	–	8,705	–	–	–	–	–	8,705
Outright donation expenses	12,350	–	–	–	12,350	–	–	–	–	–	12,350
Utilities	3,748	–	–	–	3,748	–	–	–	–	–	3,748
Other fund generating expenses	75,477	–	–	–	75,477	–	–	–	–	–	75,477
Staff Welfare	5,404	–	–	–	5,404	–	–	–	–	–	5,404
Staff Training	2,794	–	–	–	2,794	–	–	–	–	–	2,794
Staff meeting & refreshment	705	–	–	–	705	–	–	–	–	–	705
Staff insurance	5,408	–	–	–	5,408	–	–	–	–	–	5,408
	1,595,677	–	–	–	1,595,677	–	–	–	320,628	320,628	1,916,305

2014	Unrestricted funds					Restricted funds					
	General Fund	Cancer Treatment Fund	Cervical Cancer Prevention Fund	SCS-CST Matching Fund	Sub-Total	Run For Hope Fund	RGS-Joan Chan Shu Fang Fund	Koh Soh Eng Fund	Movember Fund	Sub-Total	Total
	$	$	$		$		$	$	$	$	$
EXPENSES (cont'd)											
Administrative costs											
Staff costs	241,568	–	–	–	241,568	–	–	–	–	–	241,568
Audit fee	7,674	–	–	–	7,674	–	–	–	–	–	7,674
Repair and maintenance	23,885	–	–	–	23,885	–	–	–	–	–	23,885
Rental charges	6,604	–	–	–	6,604	–	–	–	–	–	6,604
Depreciation	16,990	–	–	–	16,990	–	–	–	–	–	16,990
Refreshments	1,253	–	–	–	1,253	–	–	–	–	–	1,253
General expenses	196	–	–	–	196	–	–	–	–	–	196
Bank charges	764	–	–	–	764	30	–	–	–	30	794
Transport and traveling	1,629	–	–	–	1,629	–	–	–	–	–	1,629
Printing and stationery	5,789	–	–	–	5,789	–	–	–	–	–	5,789
Utilities	6,662	–	–	–	6,662	–	–	–	–	–	6,662
Insurance	3,804	–	–	–	3,804	–	–	–	–	–	3,804
Other expenses	740,227	–	–	–	740,227	–	–	–	–	–	740,227
Postage and courier	10,234	–	–	–	10,234	–	–	–	–	–	10,234
Staff welfare	8,718	–	–	–	8,718	–	–	–	–	–	8,718
Staff training	3,590	–	–	–	3,590	–	–	–	–	–	3,590
Staff insurance	9,615	–	–	–	9,615	–	–	–	–	–	9,615
	1,089,202	–	–	–	1,089,202	30	–	–	–	30	1,089,232
Total expenses	13,477,552	–	84,300	–	13,561,852	30	5,417	–	320,628	326,075	13,887,927
Surplus/(deficit) for the reporting year	7,123,027	32,720	(80,300)	–	7,075,447	37,891	206	(32,720)	462,652	468,029	7,543,476